Clinical Trial Update: A Study of the Safety and Antitumoral Efficacy of Nivolumab After SIRT for the Treatment of Patients With HCC [Phase 2]

View source ↗

Summary

Phase 2 study evaluating safety and antitumoral efficacy of nivolumab after selective internal radiation therapy in hepatocellular carcinoma has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hepatocellular Carcinoma

Drugs mentioned

• nivolumab (nivolumab)

Snippet

Sponsor: Clinica Universidad de Navarra, Universidad de Navarra | Conditions: Hepatocellular Carcinoma | Phase 2 | Status: COMPLETED